|
US2004033521A1
|
|
Novel core 2 beta-1, 6-N-acetylglycosaminyltransferas E gene
|
|
AU3705402A
|
|
Alkaloid halide salts of swainsonine and methods of use
|
|
AU5810701A
|
|
Designing modulators for glycosyltransferases
|
|
AU5603001A
|
|
Designing modulators for galactosyltransferases
|
|
US6593119B2
|
|
Core 2 β-1,6-N-acetylglycosaminyltransferase gene
|
|
CA2296936A1
|
|
Novel core 2 beta-1,6-n-acetylglycosaminyltransferase
|
|
CA2352858A1
|
|
Novel derivatives of swainsonine, processes for their preparation, and their use as therapeutic agents
|
|
AU5143699A
|
|
N-acetylglycosaminyl transferase genes
|
|
CA2334338A1
|
|
Directed combinatorial compound library and high throughput assays for screening same
|
|
AU9617298A
|
|
Synthesis of swainsonine salts
|
|
EP1264832A1
|
|
Alkaloid halide salts of swainsonine and methods of use
|
|
CA2286766A1
|
|
Alkaloid halide salts of swainsonine and methods of use
|
|
BR9808585A
|
|
Sw ainsonine alkali halide salts and methods of use
|
|
EP0934317A2
|
|
Novel 6 or 7 substituted analogues of swainsonine, processes for their preparation and their use as therapeutic agents
|
|
AU4374397A
|
|
Novel 3, 5, and/or 6 substituted analogues of swainsonine, processes for their preparation and their use as therapeutic agents
|
|
US5650413A
|
|
Derivatives of swainsonine, processes for their preparation and their use as therapeutic agents
|
